THERAPEUTIC MONITORING OF ANTIPSYCHOTIC DRUGS

Chromatography

THERAPEUTIC MONITORING OF ANTIPSYCHOTIC DRUGS

05 Nov, 2008

Published over 17 years ago. See the latest and most current information on Chromatography.

Dr Bob Flanagan
1 min read
Download
Schizophrenia affects some 1% of adults during their lifetime and can be a very serious illness - about 10% of patients die an unnatural death, usually suicide. In the UK some 210,000 people (worldwide of the order of 50 million) suffer from the disease. Families, friends, and others are of course affected indirectly. Today the estimated cost of treating schizophrenia is 2.5% of total healthcare costs in Western countries – for the NHS 2008-9 this amounts to some £2.4 billion; there are additional contributions from the private sector and other agencies such as the Home Office. Schizophrenia is a chronic disorder, typically arising in early adulthood and progressing throughout the rest of the individual’s life. It is slightly more common in males than females, but usually occurs earlier and is more serious in males. Symptoms are protean, but are generally characterised by three groups: • ‘Positive’: delusions, hallucinations, disorganised behaviour, impaired communication. • ‘Negative’: social withdrawal, poverty of thought and speech, blunted affect, lack of drive. • Cognitive dysfunction: affecting insight, memory, reasoning, etc.

Latest Articles

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
EU adopts sum-based PFAS and bisphenol limits for surface water and groundwater
Explore more Arrow
Pollution Solutions Online
Safe drinking water worldwide
Explore more Arrow
Petro Online
EU delays methane import penalties but leaves MRV obligations in place from 2027
Explore more Arrow
Chromatography Today
Inline degasser range upgraded with new vacuum control and pump technology
Explore more Arrow